Discontinuation of oral anticoagulation in atrial fibrillation and risk of ischaemic stroke. Issue 7 (11th December 2020)

• Record Type: Journal Article
• Authors: García Rodríguez, Luis Alberto; Cea Soriano, Lucía; Munk Hald, Stine; Hallas, Jesper; Balabanova, Yanina; Brobert, Gunnar; Vora, Pareen; Sharma, Mike; Gaist, David
• Is Part Of: Heart. Volume 107:Issue 7(2021)
• Page Start: 542
• Page End: 548
• Publication Date: 2020-12-11
• Subjects: atrial fibrillation -- stroke -- epidemiology -- electronic medical records; Heart -- Diseases -- Treatment -- Periodicals; Cardiology -- Periodicals; 616.12
• DOI: 10.1136/heartjnl-2020-317887
• Languages: English
• ISSNs: 1355-6037

Abstract

Abstract : Objective: To evaluate associations between oral anticoagulant (OAC) discontinuation and risk of ischaemic stroke (IS) among patients with atrial fibrillation (AF). Methods: We undertook a population-based cohort study with nested case–control analysis using UK primary care electronic health records (IQVIA Medical Research Data-UK) and linked registries from the Region of Southern Denmark (RSD). Patients with AF (76 882 UK, 41 526 RSD) were followed to identify incident IS cases during 2016–2018. Incident IS cases were matched by age and sex to controls. Adjusted ORs for OAC discontinuation (vs current OAC use) were calculated using logistic regression. Results: We identified 616 incident IS cases in the UK and 643 in the RSD. ORs for IS with any OAC discontinuation were 2.99 (95% CI 2.31 to 3.86, UK) and 2.30 (95% CI 1.79 to 2.95, RSD), for vitamin K antagonist discontinuation they were 2.38 (95% CI 1.72 to 3.30, UK) and 1.83 (95% CI 1.34 to 2.49, RSD), and for non-vitamin K antagonist oral anticoagulant discontinuation they were 4.59 (95% CI 2.97 to 7.08, UK) and 3.37 (95% CI 2.35 to 4.85, RSD). ORs were unaffected by time since discontinuation and duration of use. Annually, up to 987 IS cases in the UK and 132 in Denmark could be preventable if OAC therapy is not discontinued. Conclusions: Our results suggest that patients with AF who discontinue OAC therapy have a significant twofold to threefold higher risk of IS compared with those who continue therapy. Addressing OAC discontinuation could potentially result in a significant reduction in AF-attributed IS.